Reference
Parisi A, et al. Clinicians' Attitude to Doublet Plus Anti-EGFR Versus Triplet Plus Bevacizumab as First-line Treatment in Left-Sided RAS and BRAF Wild-Type Metastatic Colorectal Cancer Patients: A Multicenter, "Real-Life", Case-Control Study. Clinical Colorectal Cancer 20: 318-325, No. 4, Dec 2021. Available from: URL: http://doi.org/10.1016/j.clcc.2021.07.003
Rights and permissions
About this article
Cite this article
Antineoplastics/folinic acid. Reactions Weekly 1893, 49 (2022). https://doi.org/10.1007/s40278-022-09832-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40278-022-09832-x